Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
SQZ Biotechnologies Co (SQZ)
|
Add to portfolio |
|
|
|
| Price: |
$10.42
| | Metrics |
| OS: |
29.5
|
M
| |
-288
|
% ROE
|
| Market cap: |
$307
|
M
| |
-149
|
% ROIC
|
|
Net cash:
|
$24.7
|
M
| |
$0.84
|
per share
|
|
EV:
|
$283
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($29.7)
|
M
| |
|
|
|
EBIT
|
($31.0)
|
M
| |
|
|
| EPS |
$4.30
| |
2.4
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 21.5 | 27.1 | 21.0 | 20.1 | 12.7 |
| Revenue growth | -20.7% | 29.1% | 4.4% | 58.7% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 21.5 | 27.1 | 21.0 | 20.1 | 12.7 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | 26.3 | 25.7 | 72.1 | 18.3 | 8.7 |
| Research and development | 71.0 | 70.1 | | 36.1 | 24.4 |
| EBIT | -75.8 | -68.8 | -50.0 | -34.3 | -20.4 |
| EBIT margin | -353.0% | -253.8% | -238.0% | -170.4% | -161.1% |
| Pre-tax income | 79.5 | -68.7 | -50.5 | -32.2 | -19.3 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -79.5 | -68.7 | -50.5 | -32.2 | -20.2 |
| Net margin | -370.0% | -253.7% | -240.6% | -160.1% | -159.7% |
| |
| Diluted EPS | $2.76 | ($2.49) | ($9.35) | ($18.89) | ($12.75) |
| Shares outstanding (diluted) | 28.8 | 27.6 | 5.4 | 1.7 | 1.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|